Close this search box.

Evotec names Christian Wojczewski CEO

ARTICLE | Management Tracks

Plus: Novartis proposes Giovanni Caforio as chair and updates from Congruence, Recludix, Calluna and more

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst 

April 24, 2024 12:17 AM UTC

Evotec SE (Xetra:EVT; NASDAQ:EVO) named Christian Wojczewski CEO, effective July 1. Wojczewski, who was CEO of Mediq and Linde GmbH, will succeed interim CEO Mario Polywka, who took on the role in January following the resignation of CEO Werner Lanthaler. Evotec added that Polywka will retire from his position and not seek re-election to the company’s board. 

Novartis AG (SIX:NOVN; NYSE:NVS) proposed Giovanni Caforio to succeed Chair Joerg Reinhardt, whose 12-year term will end in 2025. Caforio joined Bristol Myers Squibb Co. (NYSE:BMY) in 2000, and served as CEO from 2015 to 2023, chairman from 2017 until 2023, and executive chairman from 2023 until March. Shareholders will vote on the nomination at the company’s next annual general meeting, which usually occurs in March. …